drugset / Trial / NCT03220126

A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants

NCT03220126

Phase 1 Completed 72 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given together with LY9999QS compared to LY3074828 alone. The tolerability of the different formulations will also be evaluated and information about any side effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant the total duration of the clinical trial will be approximately 13 weeks, not including screening.

Timeline

Start
2017-07-17
Primary completion
2018-02-23
Completion
2018-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject LY9999QS Unknown Subcutaneous
Subject Mirikizumab Monoclonal antibody Intravenous

Indications

No indication recorded.